Vaccine effects on COVID-19 infection with bivalent boosting by age group

IF 15.8 1区医学 Q1 PHARMACOLOGY & PHARMACY

Drug Resistance Updates Pub Date : 2023-12-27 DOI:10.1016/j.drup.2023.101039

Yoshiyasu Takefuji

引用次数: 0

Abstract

This paper examines time-series vaccine effectiveness on COVID-19 infection with/without a bivalent booster dose by 6 age groups such as 18–29, 30–49, 50–64, 65–79, 80+, and all_ages respectively. CDC’s COVID data on rates of COVID-19 cases and deaths by updated (bivalent) booster status was used in this study. This result concludes that there is no difference between vaccines with or without a bivalent booster dose for preventing COVID-19 infection in 6 age groups 18–29, 30–49, 50–64, 65–79, 80+, and all_ages. Vaccination is effective in two age groups of 65-79 and 80+ for preventing COVID-19 infection. However, vaccine effectiveness against COVID-19 infection has not been confirmed in the 18–29 and 30–49 age groups.

查看原文本刊更多论文

按年龄组划分的二价强化疫苗对 COVID-19 感染的影响

本文按 18-29 岁、30-49 岁、50-64 岁、65-79 岁、80 岁以上和所有年龄等 6 个年龄组分别研究了接种/未接种二价加强剂的 COVID-19 感染疫苗的时间序列效果。本研究采用了美国疾病预防控制中心的 COVID 数据，即按最新（二价）强化剂情况分列的 COVID-19 病例率和死亡率。结果表明，在 18-29 岁、30-49 岁、50-64 岁、65-79 岁、80 岁以上和所有年龄段的 6 个年龄组中，接种或不接种二价强化剂疫苗在预防 COVID-19 感染方面没有差异。65-79 岁和 80 岁以上两个年龄组接种疫苗可有效预防 COVID-19 感染。但在 18-29 岁和 30-49 岁年龄组中，疫苗对预防 COVID-19 感染的有效性尚未得到证实。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Resistance Updates 医学-药学

CiteScore

26.20

自引率

11.90%

发文量

审稿时长

29 days

期刊介绍： Drug Resistance Updates serves as a platform for publishing original research, commentary, and expert reviews on significant advancements in drug resistance related to infectious diseases and cancer. It encompasses diverse disciplines such as molecular biology, biochemistry, cell biology, pharmacology, microbiology, preclinical therapeutics, oncology, and clinical medicine. The journal addresses both basic research and clinical aspects of drug resistance, providing insights into novel drugs and strategies to overcome resistance. Original research articles are welcomed, and review articles are authored by leaders in the field by invitation. Articles are written by leaders in the field, in response to an invitation from the Editors, and are peer-reviewed prior to publication. Articles are clear, readable, and up-to-date, suitable for a multidisciplinary readership and include schematic diagrams and other illustrations conveying the major points of the article. The goal is to highlight recent areas of growth and put them in perspective. *Expert reviews in clinical and basic drug resistance research in oncology and infectious disease *Describes emerging technologies and therapies, particularly those that overcome drug resistance *Emphasises common themes in microbial and cancer research